ライフサイエンスコーパス: Waldenstrom

1 Waldenstrom macroglobulinaemia is an indolent B-cell lym

2 Waldenstrom macroglobulinemia (WM) cells present with in

3 Waldenstrom macroglobulinemia (WM) is a B-cell disorder

4 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

5 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

6 Waldenstrom macroglobulinemia (WM) is a B-cell malignanc

7 Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm

8 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

9 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

10 Waldenstrom macroglobulinemia (WM) is a distinct B-cell

11 Waldenstrom macroglobulinemia (WM) is a lymphoid neoplas

12 Waldenstrom macroglobulinemia (WM) is a proliferative di

13 Waldenstrom macroglobulinemia (WM) is a rare, lymphoplas

14 Waldenstrom macroglobulinemia (WM) is an incurable low-g

15 Waldenstrom macroglobulinemia (WM) is an incurable low-g

16 Waldenstrom macroglobulinemia (WM) is an incurable low-g

17 Waldenstrom macroglobulinemia (WM) is an incurable lymph

18 Waldenstrom macroglobulinemia (WM) is an uncommon lympho

19 Waldenstrom macroglobulinemia (WM) is characterized by w

20 Waldenstrom macroglobulinemia (WM) is preceded by asympt

21 Waldenstrom macroglobulinemia (WM), a distinctive subtyp

22 Waldenstrom macroglobulinemia (WM), an IgM-associated ly

23 Waldenstrom macroglobulinemia (WM), which has an immunog

24 Waldenstrom macroglobulinemia is a distinct low-grade ly

25 Waldenstrom macroglobulinemia is a similar disease with

26 Waldenstrom's macroglobulinemia (WM) is a distinct clini

27 Waldenstrom's Macroglobulinemia (WM) is an IgM-secreting

28 Waldenstrom's macroglobulinemia (WM) is characterized by

29 Waldenstrom's macroglobulinemia is an incurable, IgM-sec

30 large B-cell lymphoma (ABC DLBCL) and BCWM.1 Waldenstrom macroglobulinemia (WM) xenografted mice with

31 (n = 4, 22%), multiple myeloma (n = 2, 11%), Waldenstrom's macroglobulinemia (n = 2, 11%), extranodal

32 Risks for non-Hodgkin lymphoma (n = 1359), Waldenstrom macroglobulinemia (n = 165), and cryoglobuli

33 ic leukemia (Richter transformation; n = 7), Waldenstrom macroglobulinemia (n = 4), and marginal zone

34 d in 17 patients (relative risk [RR], 14.8), Waldenstrom macroglobulinemia in 6 (RR, 262), primary am

35 cil to Fludarabine in Patients With Advanced Waldenstrom Macroglobulinemia) was undertaken in 101 cen

36 a (MM) than chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia; that T cells are more pr

37 lymphoma, diffuse large B cell lymphoma and Waldenstrom macroglobulinaemia.

38 from patients with mantle cell lymphoma and Waldenstrom macroglobulinemia.

39 ic leukemia (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

40 phoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenstrom macroglobulinemia (WM), between 01-Jan-2008

41 ificance (MGUS), multiple myelomas (MM), and Waldenstrom's macroglobulinemias (WM) using protein macr

42 ry, acute myeloid leukemia/myelofibrosis and Waldenstrom macroglobulinemia/myeloma.

43 Multiple myeloma and Waldenstrom macroglobulinemia are incurable hematologic

44 enetic abnormalities in multiple myeloma and Waldenstrom macroglobulinemia have implications for dise

45 ples from patients with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal

46 ght-chain amyloidosis, multiple myeloma, and Waldenstrom macroglobulinemia.

47 tions, and myelokathexis (WHIM) syndrome and Waldenstrom macroglobulinemia, we demonstrated that muta

48 rom other IgM-producing gammopathies such as Waldenstrom macroglobulinemia (WM) has not been well cha

49 ned significance (IgM-MGUS) and asymptomatic Waldenstrom macroglobulinemia (WM; aWM) are precursor co

50 patients (36%), with the most frequent being Waldenstrom macroglobulinemia (n = 9, 20%).

51 CD56(-) MM cell lines, as well as a CD56(-) Waldenstrom's macroglobulinemia cell line.

52 B-cell morphology revealed that plasma cell Waldenstrom macroglobulinemia samples most closely resem

53 dults aged 18 years and older with confirmed Waldenstrom's macroglobulinaemia, refractory to rituxima

54 inemia that can be useful in differentiating Waldenstrom's macroglobulinemia and non-IgM LPL from B-c

55 For Waldenstrom macroglobulinemia (WM), a distinct subtype o

56 cal evaluation of investigational agents for Waldenstrom macroglobulinemia (WM) has been limited by t

57 The genetic basis for Waldenstrom macroglobulinemia (WM) remains to be clarifi

58 The treatment options for Waldenstrom macroglobulinaemia continued to be researche

59 Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM).

60 emotherapy is a cornerstone of treatment for Waldenstrom's macroglobulinemia (WM).

61 In the era of widespread rituximab use for Waldenstrom's macroglobulinaemia, new treatment options

62 ording to the 6th International Workshop for Waldenstrom Macroglobulinemia (IWWM) and the modified 3r

63 nels at previous International Workshops for Waldenstrom Macroglobulinaemia (IWWM).

64 utation in benign monoclonal IgM gammopathy, Waldenstrom's macroglobulinemia, and diffuse large B cel

65 a, 2 had classic Hodgkin lymphoma, and 2 had Waldenstrom macroglobulinemia.

66 rapeutic targeting, such as interleukin-6 in Waldenstrom macroglobulinemia.

67 tigate and report its aberrant activation in Waldenstrom macroglobulinemia (WM).

68 ations including MYD88, CXCR4, and ARID1A in Waldenstrom macroglobulinemia (WM).

69 ling in malignant lymphoplasmacytic cells in Waldenstrom macroglobulinemia (WM).

70 MYD88 and CXCR4 mutations are common in Waldenstrom macroglobulinemia (WM).

71 (95%-97%) and CXCR4 (30%-40%) are common in Waldenstrom macroglobulinemia (WM).

72 atic mutations in MYD88 (L265P) and CXCR4 in Waldenstrom macroglobulinemia (WM).

73 mbination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediat

74 Proteasome inhibitors are effective in Waldenstrom's macroglobulinemia (WM) but require parente

75 gnificance of IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma ch

76 t of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM).

77 inhibition has not yet been investigated in Waldenstrom macroglobulinemia (WM).

78 nical models, the role of these molecules in Waldenstrom macroglobulinemia (WM) remains poorly unders

79 hemokine receptor type 4 (CXCR4) mutation in Waldenstrom macroglobulinemia (WM), a marker of tumor ag

80 8 (L265P) is a recurring somatic mutation in Waldenstrom's macroglobulinemia (WM).

81 has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM), including MYD88 (95%

82 has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM).

83 derstand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody

84 portant information on the cell of origin in Waldenstrom macroglobulinemia (WM), a longstanding puzzl

85 atment-related peripheral neuropathy (PN) in Waldenstrom's macroglobulinemia (WM).

86 265P somatic mutation is highly prevalent in Waldenstrom macroglobulinemia (WM) and supports malignan

87 XCR4(WHIM) mutations are highly prevalent in Waldenstrom's macroglobulinemia.

88 ironment) that regulate tumor progression in Waldenstrom macroglobulinemia.

89 igh response rates and durable remissions in Waldenstrom macroglobulinemia (WM) that are impacted by

90 study examining fludarabine and rituximab in Waldenstrom macroglobulinemia (WM).

91 sustained efficacy of ibrutinib-rituximab in Waldenstrom's macroglobulinemia (WM).

92 n, as well as NF-kappaB nuclear staining, in Waldenstrom's macroglobulinemia cells expressing MYD88 L

93 ictate clinical presentation and survival in Waldenstrom macroglobulinemia (WM).

94 r approach and its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has

95 ell lymphoproliferative disorders, including Waldenstrom macroglobulinemia (WM) and chronic lymphocyt

96 ic of several B cell malignancies, including Waldenstrom macroglobulinemia (WM), where elevated IgM i

97 nesis of hematologic malignancies, including Waldenstrom macroglobulinemia (WM).

98 ies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and

99 of patients with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia [WM]), being either absent

100 lymphocytic lymphoma, mantle cell lymphoma, Waldenstrom macroglobulinaemia, or marginal zone lymphom

101 Adjusted P values for non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thy

102 = 2.9; 1.9-4.3), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM; RR = 4.0; 1.5-11)

103 ic and molecular signatures of the malignant Waldenstrom clone.

104 significance (MGUS), multiple myeloma (MM), Waldenstrom macroglobulinemia (WM) and light chain AL am

105 tiomic analysis on a series of MYD88-mutated Waldenstrom macroglobulinemia (WM) patients and identifi

106 Observations: Waldenstrom macroglobulinemia remains a rare, incurable

107 or kappaB activity and is present in >90% of Waldenstrom macroglobulinemia (WM) patients.

108 ype diffuse large B-cell lymphoma and 90% of Waldenstrom macroglobulinemia, making it conceptually at

109 Familial aggregation of Waldenstrom macroglobulinemia (WM) and related B-cell di

110 Familial aggregation of Waldenstrom macroglobulinemia (WM) cases, and the cluste

111 both in the understanding of the biology of Waldenstrom macroglobulinemia (WM) and in therapeutic op

112 thy of uncertain significance, and 1 case of Waldenstrom's macroglobulinemia.

113 Multilevel genetic characterization of Waldenstrom macroglobulinemia (WM) is required to improv

114 he bone marrow biopsy specimen, diagnosis of Waldenstrom macroglobulinemia was established, and compu

115 Inflammatory form of Waldenstrom macroglobulinemia (iWM) predicts outcomes af

116 of MyD88, which is mutated in a fraction of Waldenstrom macroglobulinemia.

117 e of a 77-year-old white man with history of Waldenstrom's macroglobulinemia transforming to large B-

118 ormation about the molecular pathogenesis of Waldenstrom macroglobulinemia (WM) has significantly adv

119 the advances observed in the pathogenesis of Waldenstrom macroglobulinemia.

120 ymphoma overall, and a 3-fold higher risk of Waldenstrom macroglobulinemia, a low-grade lymphoma.

121 Profiling performed after separation of Waldenstrom macroglobulinemia samples into populations w

122 A whole exome-sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high freq

123 Histologic transformation of Waldenstrom macroglobulinemia (HT-WM) carries a poor pro

124 resent emerging options for the treatment of Waldenstrom macroglobulinaemia.

125 ed as appropriate agents in the treatment of Waldenstrom macroglobulinemia (WM), a lymphoplasmacytic

126 consensus panel based on their expertise on Waldenstrom macroglobulinaemia.

127 Current information on Waldenstrom macroglobulinemia (WM) is based on retrospec

128 nsus panels of the International Workshop on Waldenstrom's Macroglobulinemia (IWWM).

129 patients with heavily pretreated MM (22) or Waldenstrom macroglobulinemia (3) were administered seli

130 (IgM) class, which progresses to lymphoma or Waldenstrom macroglobulinemia, whereas IgA and IgG MGUS

131 as splenic marginal zone B-cell lymphoma or Waldenstrom macroglobulinemia.

132 ificance, smoldering plasma cell myeloma, or Waldenstrom macroglobulinemia.

133 Following profiling, Waldenstrom macroglobulinemia samples clustered with chr

134 th treatment-naive, or relapse or refractory Waldenstrom macroglobulinemia.

135 rolimus in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

136 tuximab in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

137 inostat in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

138 had heavily pretreated, rituximab-refractory Waldenstrom's macroglobulinaemia.

139 had heavily pretreated, rituximab-refractory Waldenstrom's macroglobulinaemia.

140 mumab monotherapy for untreated and relapsed Waldenstrom's macroglobulinaemia.

141 ho were diagnosed with untreated or relapsed Waldenstrom's macroglobulinaemia and required treatment,

142 ytic lymphoma (LPL), including IgM-secreting Waldenstrom macroglobulinemia (WM).

143 ion and survival of patients with smoldering Waldenstrom macroglobulinemia (SWM).

144 ing thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to eit

145 4 years), 34 (71%) progressed to symptomatic Waldenstrom macroglobulinemia (WM) requiring treatment,

146 the International Prognostic Scoring System Waldenstrom Macroglobulinaemia, median number of previou

147 ays normalized once the transcriptome of the Waldenstrom B-cell clone was compared with its normal ph

148 Interestingly, the transcriptome of the Waldenstrom B-cell clone was highly different than that

149 r refractory (at least one previous therapy) Waldenstrom macroglobulinemia that required treatment, a

150 four small lymphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal

151 en with systemic treatment of the underlying Waldenstrom macroglobulinemia, the visual prognosis was

152 BDR) in patients with symptomatic, untreated Waldenstrom macroglobulinemia (WM).

153 early universal in multiple myeloma, whereas Waldenstrom macroglobulinemia generally does not harbor

154 xome sequencing data in 34 subjects (23 with Waldenstrom macroglobulinemia [WM], 6 with IgM monoclona

155 with splenic marginal zone lymphoma, 29 with Waldenstrom macroglobulinemia, and 57 with B-cell chroni

156 ryopyrin-associated periodic disease, 9 with Waldenstrom disease, and 10 with chronic spontaneous urt

157 t(9;14)(p13;q32), previously associated with Waldenstrom's macroglobulinemia and lymphoplasmacytoid l

158 lly with thymoma, a myopathy associated with Waldenstrom's macroglobulinemia, Lambert-Eaton myastheni

159 Four patients (8 eyes) with Waldenstrom macroglobulinemia and serous retinal detachm

160 found among RFs from HID or individuals with Waldenstrom's macroglobulinemia who do not have joint di

161 elated clones in the blood of a patient with Waldenstrom macroglobulinemia (WM) indicates the functio

162 A monoclonal IgM from a patient with Waldenstrom's macroglobulinemia hydrolyzed Abeta40 at th

163 In previously treated patients with Waldenstrom macroglobulinaemia who had an initial durabl

164 herapy options for symptomatic patients with Waldenstrom macroglobulinaemia.

165 We included patients with Waldenstrom macroglobulinemia (WM) and a radiologic and/

166 Treatment options for patients with Waldenstrom macroglobulinemia (WM) and closely related d

167 YD88 L265P somatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight i

168 Patients with Waldenstrom macroglobulinemia (WM) have disparate outcom

169 The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously.

170 resent in approximately 95% of patients with Waldenstrom macroglobulinemia (WM), as well as other B-c

171 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM), most of which were o

172 fective treatment approach for patients with Waldenstrom macroglobulinemia (WM).

173 brand syndrome is described in patients with Waldenstrom macroglobulinemia (WM).

174 otherapy in previously treated patients with Waldenstrom macroglobulinemia (WM).

175 nubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia (WM).

176 eviously untreated symptomatic patients with Waldenstrom macroglobulinemia (WM).

177 The records of patients with Waldenstrom macroglobulinemia and OCT documentation of s

178 of 6q is identified in 50% of patients with Waldenstrom macroglobulinemia, however.

179 and safety of acalabrutinib in patients with Waldenstrom macroglobulinemia.

180 cally the standard of care for patients with Waldenstrom macroglobulinemia; however, infectious and h

181 erapeutic treatment option for patients with Waldenstrom's macroglobulinaemia, especially those with

182 esponses in previously treated patients with Waldenstrom's macroglobulinaemia.

183 emotherapeutics, is needed for patients with Waldenstrom's macroglobulinaemia.

184 malignant B cells derived from patients with Waldenstrom's macroglobulinemia (WM).

185 in tumor samples from 49 of 54 patients with Waldenstrom's macroglobulinemia and in 3 of 3 patients w

186 Two patients with Waldenstrom's macroglobulinemia and one patient with HD

187 red normal tissue samples from patients with Waldenstrom's macroglobulinemia or non-IgM LPL and in B

188 commonly recurring mutation in patients with Waldenstrom's macroglobulinemia that can be useful in di

189 of ibrutinib in 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at leas

190 In addition, 2 of 3 patients with Waldenstrom's macroglobulinemia who had wild-type MYD88

191 Among the patients with Waldenstrom's macroglobulinemia, a somatic variant (T-->

192 of bone marrow LPL cells in 30 patients with Waldenstrom's macroglobulinemia, with paired normal-tiss

193 at we previously analyzed from patients with Waldenstrom's macroglobulinemia.

194 ponses, and safe in pretreated patients with Waldenstrom's macroglobulinemia.

195 d lymphoplasmacytic lymphoma with or without Waldenstrom's macroglobulinemia (10).

196 tients with iNHL (follicular, marginal zone, Waldenstrom macroglobulinemia) treated with chemotherapy